Is Syncom Formul. overvalued or undervalued?

As of 26 September 2025, the valuation grade for Syncom Formulations has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 29.09, a price-to-book value of 4.89, and an EV to EBITDA ratio of 26.26. These ratios suggest that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, Syncom's valuation metrics are notably higher than those of Cipla, which has a PE ratio of 22.45, and Dr. Reddy's Labs, with a PE of 18.4. Additionally, while the PEG ratio for Syncom is relatively low at 0.29, indicating potential growth, it remains overshadowed by the high absolute valuation levels. Recent performance shows that Syncom has underperformed the Sensex over the past year, with a return of -16.51% compared to the Sensex's -6.30%, reinforcing the view that the stock may be overvalued in the current market context.